Recordati SpAMEX:RECN 71 PE Ratio without NRI is 19.59 as of Jun. 25, 2026, which is 20% below its 10-year median of 24.41. GuruFocus rates MEX:RECN with a GF Score™ of 71/100 and a GF Value™ of MXN1,150.22 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 653 Drug Manufacturers companies, Recordati SpA ranks worse than 51% on this metric.
The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-06-25), Recordati SpA's share price is MXN1019.79.
Recordati SpA's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was MXN52.03. Therefore, Recordati SpA's PE Ratio without NRI for today is 19.59.
During the past 13 years, Recordati SpA's highest PE Ratio without NRI was 32.34. The lowest was 18.78. And the median was 24.41.
Recordati SpA's EPS without NRI for the
three
months ended in Mar. 2026 was MXN15.60.
Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was MXN52.03.
Recordati SpA stock PE Ratio (=22.53) is close to 3-year low of 21.07.
During the past years, Recordati SpA's highestPE Ratio (TTM) was 32.90. The lowest was 19.01. And the median was 25.47.
Recordati SpA's
EPS (Diluted) for the
three
months ended in Mar. 2026 was MXN15.26.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was MXN47.88.
Recordati SpA's EPS (Basic) for the
three
months ended in Mar. 2026 was MXN15.64.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was MXN48.90.
Recordati SpA (MEX:RECN) PE Ratio without NRI Explanation
The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.
If a company loses money, the PE Ratio becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.
Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.
Recordati SpA PE Ratio without NRI Related Terms
Recordati SpA PE Ratio without NRI Historical Data
* Premium members only.
The historical data trend for Recordati SpA's PE Ratio without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:RECN vs LLY, JNJ, ABBV: PE Ratio without NRI Comparison
For the Drug Manufacturers - General subindustry, Recordati SpA's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Recordati SpA PE Ratio without NRI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Recordati SpA's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Recordati SpA's PE Ratio without NRI falls into.
The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.
Recordati SpA's PE Ratio without NRI for today is calculated as
Recordati SpA's Share Price of today is MXN1019.79.
Recordati SpA's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN52.03.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.
For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Recordati SpA (MEX:RECN) has a PE Ratio without NRI of 19.59 as of Jun. 25, 2026. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Recordati SpA and its competitors. This is 20% below median its historical median of 24.41. Over the past decade, Recordati SpA's PE Ratio without NRI has ranged from 18.78 to 32.34. According to the industry distribution chart, Recordati SpA ranks #333 out of 653 companies in the Drug Manufacturers industry, placing it in the top 51%.
Is Recordati SpA's PE Ratio without NRI too high?
Recordati SpA's current PE Ratio without NRI of 19.59 is 20% below median its 10-year median of 24.41. Over the past 10 years, this metric has ranged from a low of 18.78 to a high of 32.34. The Drug Manufacturers industry median PE Ratio without NRI is 20.48. Recordati SpA's value of 19.59 is 4.3% below this industry median. Based on the distribution chart, Recordati SpA ranks #333 out of 653 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Recordati SpA has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Recordati SpA's PE Ratio without NRI compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Recordati SpA ranks #333 out of 653 companies for PE Ratio without NRI. This places Recordati SpA in the lower half of its industry. The industry median PE Ratio without NRI is 20.48. Recordati SpA's value of 19.59 is 4.3% below this benchmark. Historically, Recordati SpA's own PE Ratio without NRI has ranged from 18.78 to 32.34 over the past decade. While the company's 10-year median is 24.41 vs. the industry median of 20.48, Recordati SpA has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio without NRI for a Drug Manufacturers company?
The median PE Ratio without NRI among Drug Manufacturers companies is 20.48, based on 653 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio without NRI significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Recordati SpA's current PE Ratio without NRI of 19.59 is 4.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio without NRI mean?
A high PE Ratio without NRI can signal that a stock is expensive relative to its fundamentals. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Recordati SpA and its competitors. For the Drug Manufacturers industry, the median PE Ratio without NRI is 20.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Recordati SpA's current PE Ratio without NRI is 19.59, which is 20% below median its own 10-year median of 24.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recordati SpA stock overvalued right now?
Based on GuruFocus' analysis, Recordati SpA (MEX:RECN) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN1,150.22, compared to a current price of MXN1,019.79 — trading 11.3% below its estimated fair value. The current PE Ratio without NRI is 19.59, which is 20% below median its 10-year median of 24.41 and 4.3% below the Drug Manufacturers industry median of 20.48. Recordati SpA's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio without NRI calculated?
PE Ratio without NRI is calculated from a company's financial statements. For Recordati SpA (MEX:RECN), the current PE Ratio without NRI is 19.59 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Recordati SpA (MEX:RECN) Overvalued in 2026?
Based on GuruFocus' analysis, Recordati SpA stock appears to be undervalued.
The current stock price of MXN1,019.79 is trading 11.3% below its estimated GF Value™ of MXN1,150.22.
GuruFocus considers Recordati SpA to be Modestly Undervalued.
Key valuation signals for MEX:RECN:
PE Ratio without NRI: 19.59 (20% below median its 10-year median of 24.41)
GF Value™: MXN1,150.22 vs. price of MXN1,019.79 (11.3% below fair value)
Industry Position: 4.3% below the Drug Manufacturers median (#333 of 653)
No single metric tells the full story. See the MEX:RECN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Recordati SpA is engaged in the development, production, and marketing of pharmaceutical products or of pharmaceutical chemicals. The Company operates in a broad and diverse context, which includes general medicine, specialist medicine, self-medication, and rare diseases. In addition, it is also active in the field of urology, with treatments for benign prostatic hyperplasia and male functional disorders, and in psychiatry. The Company's only operating segment is the Specialty & Primary Care segment. Its geographic areas are Europe, Australasia, America, and Africa.
71GF Score
Get the complete analysis for MEX:RECN
PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:RECN has been successfully added to your 
